Patrick Peterson

3.3k total citations · 2 hit papers
55 papers, 2.6k citations indexed

About

Patrick Peterson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Patrick Peterson has authored 55 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 45 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Patrick Peterson's work include Lung Cancer Treatments and Mutations (45 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Patrick Peterson is often cited by papers focused on Lung Cancer Treatments and Mutations (45 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Patrick Peterson collaborates with scholars based in United States, Italy and Germany. Patrick Peterson's co-authors include Katherine P. Sugarman, Giorgio V. Scagliotti, Frank V. Fossella, William J. John, J. Blatter, Lorinda Simms, Nasser H. Hanna, Frances A. Shepherd, Chandra P. Belani and Maciej Krzakowski and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Patrick Peterson

54 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

2009 832 citations Tudor–Eliade Ciuleanu, Thomas Brodowicz et al. profile →
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

2009 568 citations Giorgio V. Scagliotti, Frank V. Fossella et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Peterson United States	21	2.2k	1.8k	472	310	166	55	2.6k
Purvish Parikh India	9	2.1k 1.0×	1.8k 1.0×	521 1.1×	412 1.3×	186 1.1×	21	2.6k
Cesare Gridelli Italy	18	2.4k 1.1×	2.1k 1.2×	527 1.1×	270 0.9×	179 1.1×	37	2.9k
Saulius Cicėnas Lithuania	12	1.4k 0.6×	1.1k 0.6×	320 0.7×	230 0.7×	137 0.8×	45	1.7k
Klára Szondy Hungary	6	1.8k 0.8×	1.6k 0.9×	372 0.8×	204 0.7×	104 0.6×	11	2.1k
Michael McCleod United States	17	1.7k 0.8×	2.5k 1.4×	410 0.9×	276 0.9×	227 1.4×	44	3.0k
Isabel Bover Spain	13	1.3k 0.6×	1.3k 0.7×	401 0.8×	247 0.8×	204 1.2×	48	2.1k
Jessica Menis Italy	21	1.1k 0.5×	1.2k 0.6×	381 0.8×	363 1.2×	145 0.9×	76	1.9k
Shelley Coleman United States	7	1.9k 0.9×	2.8k 1.5×	399 0.8×	387 1.2×	123 0.7×	10	3.2k
Shaharyar Canada	5	1.7k 0.8×	1.5k 0.8×	347 0.7×	210 0.7×	105 0.6×	6	2.0k
Maen Hussein United States	15	1.7k 0.8×	2.5k 1.4×	249 0.5×	224 0.7×	158 1.0×	46	2.9k

Countries citing papers authored by Patrick Peterson

Since Specialization

Citations

This map shows the geographic impact of Patrick Peterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Peterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Peterson more than expected).

Fields of papers citing papers by Patrick Peterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Peterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Peterson. The network helps show where Patrick Peterson may publish in the future.

Co-authorship network of co-authors of Patrick Peterson

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Peterson. A scholar is included among the top collaborators of Patrick Peterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Peterson. Patrick Peterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gautschi, Oliver, Keunchil Park, Benjamin Solomon, et al.. (2025). Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 43(15). 1758–1764. 4 indexed citations

Park, K., Edurne Arriola, M. Pérol, et al.. (2024). P1.12B.10 Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 19(10). S205–S205. 1 indexed citations

Whipple, Samuel, et al.. (2024). HSR24-128: Real-World Treatment Patterns and Effectiveness of Selpercatinib in Patients With Locally Advanced/Metastatic Non–Small Cell Lung Cancer in the US. Journal of the National Comprehensive Cancer Network. 22(2.5). 1 indexed citations

Ogata, Takatsugu, Yukiya Narita, Zev A. Wainberg, et al.. (2023). Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. Journal of the Korean Gastric Cancer Association. 23(2). 289–289. 1 indexed citations

Bhandari, Naleen Raj, Lisa M. Hess, Dan He, & Patrick Peterson. (2023). Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database. Journal of the National Comprehensive Cancer Network. 21(9). 934–944.e1. 6 indexed citations

Hess, Lisa M., et al.. (2023). Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States. Cancer Treatment and Research Communications. 37. 100761–100761.

Gadgeel, Shirish M., Jhanelle E. Gray, Maria Teresa Rizzo, et al.. (2022). Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189. JTO Clinical and Research Reports. 3(11). 100389–100389. 2 indexed citations

Garon, Edward B., Patrick Peterson, Maria Teresa Rizzo, & Jong Seok Kim. (2021). Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies. Clinical Lung Cancer. 23(3). 253–263. 3 indexed citations

Garon, Edward B., Joachim G.J.V. Aerts, Catherine E. Muehlenbein, et al.. (2021). Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Lung Cancer. 155. 53–60. 10 indexed citations

10.

Scagliotti, Giorgio V., Cesare Gridelli, Filippo de Marinis, et al.. (2014). Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Lung Cancer. 85(3). 408–414. 18 indexed citations

11.

Shah, Manan, Katherine B. Winfree, Patrick Peterson, et al.. (2013). Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. Lung Cancer. 82(1). 121–127. 11 indexed citations

12.

Belani, Chandra P., Thomas Brodowicz, Tudor–Eliade Ciuleanu, et al.. (2012). Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. The Lancet Oncology. 13(3). 292–299. 56 indexed citations

13.

Belani, Chandra P., Yi‐Long Wu, Yuh-Min Chen, et al.. (2011). Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial. Journal of Thoracic Oncology. 7(3). 567–573. 21 indexed citations

14.

Scagliotti, Giorgio V., Keunchil Park, Shekar Patil, et al.. (2009). Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study. European Journal of Cancer. 45(13). 2298–2303. 32 indexed citations

15.

Scagliotti, Giorgio V., Filippo de Marinis, Monica Rinaldi, et al.. (2009). The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial. Journal of Thoracic Oncology. 4(12). 1568–1571. 40 indexed citations

16.

Cullen, M.H., Petr Zatloukal, S Sörenson, et al.. (2008). A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 19(5). 939–945. 64 indexed citations

17.

Gridelli, Cesare, E. Kaukel, Vanesa Gregorc, et al.. (2007). Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial. Journal of Thoracic Oncology. 2(3). 221–229. 35 indexed citations

18.

Peterson, Patrick, Keunchil Park, Frank V. Fossella, et al.. (2007). P2-328: Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S851–S851. 94 indexed citations

19.

Vansteenkiste, Johan, Jean-Luc Canon, Henrik Riska, et al.. (2005). Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Investigational New Drugs. 23(3). 263–269. 18 indexed citations

20.

Roychowdhury, Debasish, et al.. (2002). A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy. Investigational New Drugs. 20(3). 311–315. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact